Thus, a clear benefit of anthracycline-containing chemotherapy is observed only for about 2% of the overall HER2-negative early breast cancer study population in the here presented analysis (acknowledging that in the rest of the population this pooled analysis has only 80% power to detect a 2% difference in 5-year DFS). The gene discussed is ERBB2; the disease is breast cancer.